Abstract:The growing use of molecular imaging helps to control and monitor dosage for increased safety and effectiveness. Molecular imaging agents become the scientific tools for moving a concept from bench work to clinic product development. This special issue provides original research and review of new trends in molecular imaging agent development. Among clinic molecular imaging modalities, radionuclide imaging technique is the most sensitive and could provide target-specific information. The radiotracer could non-invasively assess disease treatment endpoints which used to rely almost exclusively on biopsies and histopathological assays. L.-H. Shen et al. (Taiwan) reviewed molecular imaging in the diagnosis and management of CNS disorders. F.-L. Kong et al. (USA), N. Tsao et al. (USA), and C.-L. Ho et al. (Taiwan) report pharmacokinetics and dosimetry of molecular imaging compounds in oncology. M.-H. Liao et al. (Taiwan), X. Wang et al. (China), C. Wu et al. (China) and M. Tian et al. (USA) reported that molecular imaging techniques play a major role in the development of novel therapies since they measure target expressions (apoptosis, glycolysis) as well as function, pathway activities, and cell migration in the intact organism. Y.-F. Wang et al. and M.-Y. Chao et al. (Taiwan) described the kit probe for 99mTc-labeling which is crucial for centralized drug process. The kit probe may allow theranostic concept. A theranostic agent would be more accurate in the evaluation of patient response to treatment. The radiotracer could also be used for radionuclide therapy as reported by C. Wang et al. (China). Hybrid molecular imaging modalities (PET/CT, SPECT/CT) provide high-sensitivity functional and high-resolution anatomical imaging which are important in design-personalized treatment. M.-C. Chen et al. (Taiwan) reported the value of using I-131 NP-59 SPECT/CT to diagnose patients with subclinical or atypical features of primary aldosteronism. To proof of concept for molecular biology findings using different imaging modalities (optical, sonography) were described by Z. Pu et al. (China). In summary, molecular imaging enables the comprehensive characterization of therapeutic intervention and can be used in preclinical studies, pharmacokinetic studies, dose-finding studies, and proof-of-concept studies. Molecular imaging technologies promote the discovery and development of personalized medicine. Hong Zhang Mei Tian Carrio Ignasi Zhen Cheng Lie-Hang Shen David J. Yang

2021 Radiological Society of North America annual meeting: molecular nuclear medicine

Advances in imaging research of the digestive system tumors from 2017 annual meeting of the American Society of Clinical Oncology

The Developments and Applications of Molecular Nuclear Medicine

Molecular Image-Guided Theranostic and Personalized Medicine 2013

Advances on interventional molecular imaging

Current research in nuclear medicine and molecular imaging: highlights of the 23rd Annual EANM Congress

Molecular imaging: Moving towards infectious diseases

Research progress of molecular nuclear medicine imaging in breast cancer

Special Issue: "Molecular Imaging in Oncology: Radiopharmaceuticals for PET and SPECT 2022"

Development of nuclear medicine in oncology

APPLICATION AND PROGRESS OF MOLECULAR IMAGING IN THE DIAGNOSIS AND TREATMENT OF BRAIN TUMORS

Progress on Multi-Modality Molecular Imaging

Molecular Imaging in Medicine: Past, Present, and Future

Molecular Imaging Nanoprobes for Theranostic Applications

Nuclear medical molecular imaging of tumor angiogenesis: current status and future prospects.

Recent Advances in Molecular Image-Guided Cancer Radionuclide Therapy.

A Banner Year for Nuclear Medicine, Molecular Imaging, and Theranostics

Progress in research and application of Radiomics

Advance of Molecular Imaging Technology and Targeted Imaging Agent in Imaging and Therapy

Situation of Molecular Functional Measurement with Radionuclide Tracing Technique and Targeted Treatment

Advances in ultrasound molecular imaging